As the opioid crisis rages across the United States, a new analysis contends there is a lack of evidence that pills designed to deter abuse are truly effective in reducing overall opioid abuse and, moreover, the cost to prevent a single case of abuse or an overdose death may appear prohibitive.

After reviewing available studies, a panel of experts concluded data to support most of the so-called abuse deterrent formulations is “promising, but inconclusive,” given that some pills are new to the market or not yet available. And while studies indicated OxyContin, specifically, is harder to abuse, all of the drugs may shift people to other forms of opioids, notably heroin or fentanyl.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I’m currently on Hysingla 30mg.
    I’m awaiting implant of pain pump.
    Oh and I can’t walk and am partially paralyzed.
    Any info on Hysingla or the pain pump

    • In general, the extended release formulations are a massive ripoff. Hydrocodone is simply an effective pain medication among many. Which one works for you depends on your body chemistry. They all have problems of refractoriness. You’ll build up resistance.

      Your very brief description sounds like the intrathecal pump has good potential, maybe very good. The pump is, in essence, a way to deliver the meds directly to the spinal fluid and spinal cord without needing the blood stream to take it there. Makes each milligram or microgram 1-300 times as potent with less systemic effect. Your success will all depend on the results of a trial (never implant a pump without a positive result from a trial dose). Your success will even more depend on your doctor’s experience and ability to find the best combination of meds that work for you.

  • Do you think Purdue would really reduce the brand cost of OxyContin to that of generics? If state legislation required abuse-deterrent formulation (ADF) formulations to generic immediate-release, Purdue loses. If Purdue really cares about abuse, they will lower their OxyContin. I’m not holding my breathe though. The difference in paying out brand vs generic, can be redirected toward addiction treatment.

    “The panel noted the average price per day for an ADF pill was $11.60, compared with $5.82 for an opioid without abuse-deterrent features. ADF prices would have to drop by 41 percent to be considered worthwhile.”

  • Ed, plugging the panel’s assumptions into a clinical trial model, in order to detect a reduction of 23 abuse deterrences per 1000 patients per five years you would need a control group of equal size. That’s 2000 patients completing five years. Since this study is likely to have a high dropout rate you would have to enroll 10,000 to wind up with 2000 to show a difference of 23, assuming that your sample size calculation would show that difference to be statistically significant at P= 0.05. Such a study would cost between $50 and $100 million. If NIH wants to spend that kind of money they’re welcome to do so.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy